In addition, loss of TGFBI can induce resistance to chemotherapeutic agent paclitaxel in ovarian cancer cells [29], while human tumor cells with over-expressed levels of TGFBI showed an increased sensitivity to etoposide, paclitaxel, cisplatin and gemcitabine [10]. This evidence concerns the gene TGFBI and ovarian carcinoma.